Fekade B Sime

Stability of tigecycline in elastomeric devices for OPAT - Tigecycline meets the 🇬🇧 YCD criteria of ≤5% degradation limit. Fantastic collaboration with 🌍 colleagues ⁦@jasonroberts_pk⁩ ⁦@b_fekade⁩ ⁦@raseaton66⁩ ⁦@BSACandJAC⁩ academic.oup.com/jacamr/article…

Our article: doi.org/10.1093/jac/dk…… has been selected for inclusion in the Best of Journal of Antimicrobial Chemotherapy 2024. @b_fekade @jasonroberts_pk @CRE_RESPOND #UQCCR @UQMedicine @UQ_News academic.oup.com/jac/pages/best…

‘By standardising stability testing guidelines, we can broaden treatment options for patients with serious infections, improve clinical outcomes, advance antimicrobial stewardship, and reduce healthcare costs.’ bsac.org.uk/call-for-globa… @b_fekade @jasonroberts_pk @CRE_RESPOND @UQMedicine @UQ_News @raseaton66 @MGilchrist123

Is it time for global harmonization of opat drug stability testing frameworks? Great to collaborate with ⁦⁦@jasonroberts_pk⁩ ⁦@b_fekade⁩ ⁦⁩ ⁦@CRE_RESPOND⁩ ⁦@raseaton66⁩ ⁦@BSACandJAC⁩ & many more - onto the next step! academic.oup.com/jacamr/article…

🆕️🔥State of the art review article #JAC 🌟s @jasonroberts_pk @b_fekade @MGilchrist123 Current Practices and challenges of outpatient parenteral antimicrobial therapy #OPAT #IDXposts #bookmark Great tables🎯 academic.oup.com/jac/article/do…

In OPAT settings, continuous 12 h CZA infusion may be possible in territories where degradation of ≤10% is deemed acceptable But avoid prolonged fridge storage (>72h) to keep overall sequential degradation to <10%: doi.org/10.1093/jacamr… @b_fekade @jasonroberts_pk #JACAMRNews

Well done Mikaela, excellent talk!

Great to see this - Evaluation of stability of ceftazidime/avibactam in elastomeric infusion devices used for OPAT. 🇬🇧 & 🇦🇺 partnership in this space continues ⁦⁦@b_fekade⁩ ⁦@jasonroberts_pk⁩ ⁦@raseaton66⁩ ⁦@jamiesonce⁩ & more academic.oup.com/jacamr/article…

You're invited to an exciting 3-day workshop on Antimicrobial Optimisation: Population pharmacokinetic modeling and dosing software. 30 places available Reg: lnkd.in/dPb-X6fP @jasonroberts_pk @DocJamesPollard @legg_wamy @davidantibiotic @IATDMCT @NCICancer @PattyMitre_

You're invited to an exciting 3-day workshop on Antimicrobial Optimisation: Population pharmacokinetic modeling and dosing software. 30 places available Reg: lnkd.in/dPb-X6fP @jasonroberts_pk @DocJamesPollard @legg_wamy @SuzieParker_CMG @IATDMCT @NCICancer @PattyMitre_

@ErkuDaniel @Gebremedhinb Well done Gere!!!👏👏👏

“Laboratory-supported pharmacist-led antimicrobial stewardship can result in improved health outcomes and substantial healthcare cost savings” Findings from one of the few cost-utility studies conducted in Ethiopia. Well done @Gebremedhinb.

Join ISAC's Anti-Infective Pharmacology Working Group free of cost forms.gle/wFC6G7ZJsYJujg…

@ErkuDaniel @Menilikism @fanatelevision @ebczena እውነት!!

@Menilikism @fanatelevision @ebczena @b_fekade

Supported by @CRE_REDUCE , we published 33 papers on PK/PD of antimicrobials since 2019. Exting time as we transition to #CRE_RESPOND @jasonroberts_pk #Steategicretreat

Live Roundtable Discussion on Clinical Trials Targeting Antimicrobial Resistance with @davidantibiotic ,DR. Mo Yin and @davidlye70

@ErkuDaniel Great work @ErkuDaniel 👏👏👏

Ping @b_fekade

Fresh off the shelf: In this paper just published in @PRandP_Journal, we proposed a coherent framework for conducting economic evaluation of #TDM interventions in oncology and discussed some practical challenges. @MenziesHealth bpspubs.onlinelibrary.wiley.com/doi/10.1002/pr…

Lots happening at CRE REDUCE in the next few months! Check out our upcoming education events cre-reduce.centre.uq.edu.au/events! @jasonroberts_pk

It’s very nice to “see” everyone at #ECCMID2021. I’m struck that despite the last 18/12, so little has changed in the #AMR world. We are good at describing the problem but seem to be less interested in radical thinking that is required to minimise the impact of AMR. 1/6

Hello OPAT / HITH/ IV@home communities - antibiotic stability question for you! What buffers are used in continuous abx infusions in your service. Poll below or feel free to reply with more information! @BSACandJAC @jamiesonce @jasonroberts_pk @b_fekade @UKCPAPIN

It would make sense that high aminoglycoside concentrations achieved in the lungs after nebulisation would optimise bacterial killing for patients with pneumonia. But why has it failed in clinical trials? One potential factor is the epithelial lining fluid link.springer.com/article/10.100…